Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Nerreter

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Current Protocols in Immunology|March 10, 2020
Antibody-Based CAR T Cells Produced by Lentiviral TransductionSabrina Prommersberger, Michael Hudecek, Thomas Nerreter
Immunobiology|February 1, 2017
Robust 8-color flow cytometry panel reveals enhanced effector function of NKG2C<sup>+</sup> CD57<sup>+</sup> FcεRγ<sup>-</sup> NK cells in CMV seropositive human blood donorsThomas Nerreter, Stephan Zeiß, Thomas Herrmann, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|April 17, 2014
Karanjin interferes with ABCB1, ABCC1, and ABCG2Martin Michaelis, Florian Rothweiler, Thomas Nerreter, et al.
Experimental Hematology|March 8, 2013
Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitroThomas Nerreter, Eva Distler, Carolin Köchel, et al.
Oncogene|July 21, 2022
ROR1-targeting switchable CAR-T cells for cancer therapyHaiyong Peng, Thomas Nerreter, Katrin Mestermann, et al.
Experimental Hematology|June 3, 2014
Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3Thomas Nerreter, Christoph Köchel, Daniel Jesper, et al.
Nature Communications|July 19, 2019
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-TThomas Nerreter, Sebastian Letschert, Ralph Götz, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|April 17, 2014
Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 functionMartin Michaelis, Florian Rothweiler, Thomas Nerreter, et al.
BMC Research Notes|October 11, 2014
Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expressionMartin Michaelis, Florian Rothweiler, Thomas Nerreter, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2018
Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell PlatformJulian Rydzek, Thomas Nerreter, Haiyong Peng, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Current Protocols in Immunology|March 10, 2020
Antibody-Based CAR T Cells Produced by Lentiviral TransductionSabrina Prommersberger, Michael Hudecek, Thomas Nerreter
Immunobiology|February 1, 2017
Robust 8-color flow cytometry panel reveals enhanced effector function of NKG2C<sup>+</sup> CD57<sup>+</sup> FcεRγ<sup>-</sup> NK cells in CMV seropositive human blood donorsThomas Nerreter, Stephan Zeiß, Thomas Herrmann, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|April 17, 2014
Karanjin interferes with ABCB1, ABCC1, and ABCG2Martin Michaelis, Florian Rothweiler, Thomas Nerreter, et al.
Experimental Hematology|March 8, 2013
Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitroThomas Nerreter, Eva Distler, Carolin Köchel, et al.
Oncogene|July 21, 2022
ROR1-targeting switchable CAR-T cells for cancer therapyHaiyong Peng, Thomas Nerreter, Katrin Mestermann, et al.
Experimental Hematology|June 3, 2014
Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3Thomas Nerreter, Christoph Köchel, Daniel Jesper, et al.
Nature Communications|July 19, 2019
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-TThomas Nerreter, Sebastian Letschert, Ralph Götz, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|April 17, 2014
Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 functionMartin Michaelis, Florian Rothweiler, Thomas Nerreter, et al.
BMC Research Notes|October 11, 2014
Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expressionMartin Michaelis, Florian Rothweiler, Thomas Nerreter, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2018
Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell PlatformJulian Rydzek, Thomas Nerreter, Haiyong Peng, et al.
Pageof 3